BamSEC and AlphaSense Join Forces
Learn More

Century Therapeutics Inc. – Material Contracts

NASDAQ: IPSC    
Share price (6/25/26): $2.30    
Market cap (6/25/26): $415 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 3 pages First Amendment to the License Agreement for Use of Catalent IPSC Lines in Pre-Clinical and Clinical Development, and Commercialisation of Cell Therapies
12/34/56
EX-10.43
from 10-K 14 pages ​ Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. ​ License Agreement for Use of Catalent IPSC Lines in Pre-Clinical and Clinical Development, and Commercialisation of Cell Therapies
12/34/56
EX-10.2
from 8-K 13 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 29 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 10-Q 4 pages Century Therapeutics, Inc. 2021 Equity Incentive Plan Performance-Based Restricted Stock Unit Grant Notice and Award Agreement
12/34/56
EX-10.2
from 10-Q 10 pages Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 11 pages ​ Executive Employment Agreement
12/34/56
EX-10.2
from 8-K 13 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 23 pages Securities Purchase Agreement
12/34/56
EX-10.40
from 10-K 29 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and the Registrant Customarily and Actually Treats as Private and Confidential. License Agreement
12/34/56
EX-10.35
from 10-K 8 pages Executive Employment Agreement ​
12/34/56
EX-10.3
from 10-Q 4 pages Second Amendment to License Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Amendment No. 5 to Master Collaboration Agreement
12/34/56
EX-10.1
from 10-Q 5 pages Second Amendment to License Agreement
12/34/56
EX-10.2
from 10-Q 10 pages ​ Separation Agreement and Release
12/34/56
EX-10.1
from 10-Q 9 pages ​ Executive Employment Agreement
12/34/56
EX-10.1
from 8-K/A 7 pages April 28, 2023 Personal and Confidential Osvaldo Flores, Phd Re: Separation Agreement ● Pay You Salary Accrued to You Through Your Last Day of Employment With the Company; ● Provide You With Information on How to Continue Your Healthcare Coverage Through the Consolidated Omnibus Budget Reconciliation Act of 1985 (“Cobra”); and ● Reimburse You for Any Outstanding, Reasonable Business Expenses That You Have Incurred on the Company’s Behalf Through the Termination of Your Employment, After the Company’s Timely Receipt of Appropriate Documentation Pursuant to the Company’s Business Expense Reimbursement Policy
12/34/56
EX-10.1
from 8-K 3 pages Side Letter to Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Amendment No. 4 to Master Collaboration Agreement ​ ​
12/34/56
EX-10.31
from 10-K 85 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and the Registrant Customarily and Actually Treats as Private and Confidential. Research Collaboration and License Agreement
12/34/56